FindMyKOL
Clinical trialNCT02640833WithdrawnPhase 1Interventional

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

SponsorAbbVieEnrollment0Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaSmall Lymphocytic Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is designed to assess the safety, pharmacokinetics, drug-drug interactions, and determine the recommended Phase 2 doses of co administered Duvelisib and Venetoclax in participants with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or indolent or aggressive non-Hodgkin lymphoma, who have not previously received a Bcl-2 or Phosphoinositide 3-kinase (PI3K) inhibitor. The Phase 2 portion of the study will preliminarily evaluate efficacy, and expand the toxicity evaluation.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Site Reference Id/investigator# 145677

    Tucson, Arizona, United States

  • Site Reference Id/investigator# 147922

    Chicago, Illinois, United States

  • Site Reference Id/investigator# 148562

    Harvey, Illinois, United States

  • Site Reference Id/investigator# 148561

    Goshen, Indiana, United States

  • Site Reference Id/investigator# 145674

    Baltimore, Maryland, United States

  • Site Reference Id/investigator# 145145

    Boston, Massachusetts, United States

  • Site Reference Id/investigator# 148010

    Detroit, Michigan, United States

  • Site Reference Id/investigator# 147747

    St Louis, Missouri, United States

  • Site Reference Id/investigator# 145146

    Lebanon, New Hampshire, United States

  • Site Reference Id/investigator# 148559

    Greenville, South Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Duvelisib →Venetoclax →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2016
Primary completion
31 Jan 2020
Completion
28 Feb 2021
Last update posted
26 Jul 2016
Registered enrollment
0
Registry id
NCT02640833

Cross-registrations

EU-CTR / CTIS (EudraCT)2015-003302-16
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.